Combined Treatment with Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients with Metastatic or Inoperable Leiomyosarcoma - DiTuSarc Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Oct 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Dinutuximab beta (Primary) ; Interleukin-2 (Primary) ; Zoledronic acid (Primary)
Indications Leiomyosarcoma
Focus Therapeutic Use
Acronyms DiTuSarc

14 Oct 2024 Status changed from recruiting to active, no longer recruiting.
14 Oct 2024 Planned End Date changed from 26 Jul 2024 to 30 Jan 2025.
09 Nov 2021 Planned initiation date (estimated date for recruitment of the first subject) changed from 10 Oct 2021 to 1 Dec 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com